These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16448327)

  • 1. Insulin detemir: from concept to clinical experience.
    Home P; Kurtzhals P
    Expert Opin Pharmacother; 2006 Feb; 7(3):325-43. PubMed ID: 16448327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Perry CM
    Drugs; 2004; 64(22):2577-95. PubMed ID: 15516157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin detemir: a review of its use in the management of diabetes mellitus.
    Keating GM
    Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
    Bartley PC; Bogoev M; Larsen J; Philotheou A
    Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
    Chapman TM; Perry CM
    BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ
    Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
    Valensi P; Cosson E
    Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update).
    Philis-Tsimikas A
    Expert Opin Pharmacother; 2008 Aug; 9(12):2181-95. PubMed ID: 18671472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes.
    Umpierrez GE; Hor T; Smiley D; Temponi A; Umpierrez D; Ceron M; Munoz C; Newton C; Peng L; Baldwin D
    J Clin Endocrinol Metab; 2009 Feb; 94(2):564-9. PubMed ID: 19017758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of insulin detemir in Basal insulin therapy.
    Morales J
    Drugs; 2007; 67(17):2557-84. PubMed ID: 18034591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal insulins: Pharmacological properties and patient perspectives.
    Abrahamson MJ
    Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
    Frier BM; Russell-Jones D; Heise T
    Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis.
    Szypowska A; Golicki D; Groele L; Pańkowska E
    Pol Arch Med Wewn; 2011; 121(7-8):237-46. PubMed ID: 21878861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin detemir: a long-acting insulin product.
    Jones MC; Patel M
    Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin detemir: a new basal insulin analogue.
    Soran H; Younis N
    Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations.
    Roach P
    Clin Pharmacokinet; 2008; 47(9):595-610. PubMed ID: 18698880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.
    Raslová K; Bogoev M; Raz I; Leth G; Gall MA; Hâncu N
    Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.